Influence of Body Composition on Chemotherapy Outcomes in Localized Breast Cancer
ConditionBreast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorCentre Henri Becquerel
About this trial
The purpose of this study is to determine if pharmacokinetics of docetaxel is modified by the body composition (assessed by the BMI but also by CT-scan) in patients treated by docetaxel as adjuvant treatment of a localized breast cancer
Eligibility criteria
Qualifiers
Woman older than
Early breast cancer
CT-scan of less than 3 months, including L3 level
Indication of docetaxel at 100 mg/m² as adjuvant CT
Disqualifiers
HER2 amplified or triple negative tumors
Pregnant or breastfeeding women
Patients under guardianship or curatorship
Concomitant administration of another cytotoxic drug or targeted therapy
Trial design
Treatments tested in this trial
- pharmacokinetics blood sample assessment
Treatment groups
48 Participants
are divided into 1 treatment groupSponsors and collaborators
Centre Henri Becquerel
Lead sponsor
Erasmus Medical Center
Collaborator
Universitaire Ziekenhuizen KU Leuven
Collaborator
Source ClinicalTrials.gov